Group 1 - The overall gross margin has started to improve on a quarter-on-quarter basis, with significant growth in the backend CDMO business [2] - Domestic demand is beginning to recover, and contributions from overseas major clients provide performance elasticity [2] - The company is comprehensively laying out high-growth emerging sectors such as targeted protein degradation drugs, peptides, oligonucleotide drugs, and ADC drugs [2]